Multimodal Imaging Approach in a Patient with Vogt-Koyanagi-Harada-like Syndrome Due to Dabrafenib and Trametinib Use for Cutaneous Melanoma

Riccardo Francesco Bellancaa U.O. Oculistica 2, Turin Eye Hospital, ASL Città di Torino, Turin, Italy

https://orcid.org/0000-0002-3563-0454 View further author information

, MD

Antonio Pinnab Department of Medical, Surgical, and Experimental Sciences, Ophthalmology Unit, University of Sassari, Sassari, Italy

https://orcid.org/0000-0003-3052-2662 View further author information

, MD

Giovanna Cataniac Oncology, Carlo Poma Hospital, Mantova, ItalyView further author information

, MD,

Elena Belcastroa U.O. Oculistica 2, Turin Eye Hospital, ASL Città di Torino, Turin, Italy

https://orcid.org/0000-0003-3876-3591 View further author information

, MSc

Martina Angid Ocular Oncology Service, Department of Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

https://orcid.org/0000-0003-2703-2056 View further author information

, MD

Giuseppe D’Amico Riccia U.O. Oculistica 2, Turin Eye Hospital, ASL Città di Torino, Turin, ItalyCorrespondence[email protected]

https://orcid.org/0000-0002-9022-4790 View further author information

, MD, PhD, FEBO

References

Booth AEC, Hopkins AM, Rowland A, Kichenadasse G, Smith JR, Sorich MJ. Risk factors for MEK-associated retinopathy in patients with advanced melanoma treated with combination BRAF and MEK inhibitor therapy. Ther Adv Med Oncol. 2020;12:175883592094435. doi:10.1177/1758835920944359.
Web of Science ®Google Scholar
Dummer R, Brase JC, Garrett J, et al. Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAFV600-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trial. Lancet Oncol. 2020;21(3):358–372. doi:10.1016/S1470-2045(20)30062-0.
PubMed Web of Science ®Google Scholar
Méndez-Martínez S, Calvo P, Ruiz-Moreno O, et al. Ocular adverse events associated with MEK inhibitors. Retina. 2019;39(8):1435–1450. doi:10.1097/IAE.0000000000002451.
PubMed Web of Science ®Google Scholar
Choe CH, McArthur GA, Caro I, Kempen JH, Amaravadi RK. Ocular toxicity in BRAF mutant cutaneous melanoma patients treated with vemurafenib. Am J Ophthalmol. 2014;158(4):831–837.e2. doi:10.1016/j.ajo.2014.07.003.
PubMed Web of Science ®Google Scholar
Fujimura T, Kambayashi Y, Tanita K, et al. HLA-DRB1*04:05 in two cases of Vogt-Koyanagi-Harada disease-like uveitis developing from an advanced melanoma patient treated by sequential administration of nivolumab and dabrafenib/trametinib therapy. J Dermatol. 2018;45(6):735–737. doi:10.1111/1346-8138.14273.
PubMed Web of Science ®Google Scholar
Brambati M, Giuffrè C, Marchese A, Bandello F, Modorati GM, Miserocchi E. A case of Vogt-Koyanagi-Harada-like uveitis secondary to dabrafenib/trametinib therapy for advanced melanoma. Eur J Ophthalmol. Published online October 1, 2020. 112067212096204. 10.1177/1120672120962044
Web of Science ®Google Scholar
Miura M, Makita S, Azuma S, et al. Evaluation of retinal pigment epithelium layer change in Vogt-Koyanagi-Harada disease with multicontrast optical coherence tomography. Investig Opthalmol Vis Sci. 2019;60(10):3352. doi:10.1167/iovs.19-27378.
PubMed Web of Science ®Google Scholar

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Multimodal Imaging Approach in a Patient with Vogt-Koyanagi-Harada-like Syndrome Due to Dabrafenib and Trametinib Use for Cutaneous Melanoma

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Multimodal Imaging Approach in a Patient with Vogt-Koyanagi-Harada-like Syndrome Due to Dabrafenib and Trametinib Use for Cutaneous Melanoma

References

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date